

Table S1. Treatment and outcome profiles of COVID-19 affected in-patients.s

Characteristics	Oxygen required (n=88)	Oxygen not required (n=119)
Antibiotics		
Ceftriaxone	80 (90.9)	43 (36.1)
Ciprofloxacin	74 (84.1)	39 (32.8)
Meropenem	35 (39.8)	4 (3.4)
Tigecycline	34 (38.6)	4 (3.4)
Antiviral		
Favipiravir	6 (6.8)	7 (5.9)
Remdesivir	14 (15.9)	01 (0.8)
Antihistamine	13 (14.8)	25 (21)
Sedatives	33 (39.8)	31 (29)
Salbutamol inhaler	34 (39.5)	26 (24.5)
PPI	41 (47.1)	30 (27.3)
Long acting insulin	26 (30.6)	6 (5.6)
Short acting insulin	34 (40)	10 (9.3)
Complications	63 (71.6)	0
Heart failure	20 (22.7)	0
Septic shock	15 (17)	0
ARDS	43 (48.9)	0
Prognosis		
Discharge	62 (70.5)	116 (97.5)
Referral	7 (8)	3 (2.5)
Death	19 (21.6)	0
Hospital stay (days) (median, IQR)	9 (6, 14)	8 (4, 14)